Pregnancy, Childbirth, and HIV

IAS (International AIDS Society) Conference

The Latest

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Promo Image

Comparable Efficacy and Pregnancy Outcomes With Boosted Atazanavir and Lopinavir at Standard Doses

Retrospective data collected from nine London centres and presented at IAS 2013 suggests atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) at standard doses are comparable in efficacy and pregnancy outcomes.

In the UK and Ireland uptake o...

Promo Image

PrEP Gives Little Extra Benefit in Attempted Conception if Male Partner Is on ART

PrEP offers little extra benefit to successful and safe conception for couple with an HIV negative woman and HIV positive man if he is receiving ART, they limit unprotected sex to ovulation, and STIs are treated -- according to modelling data present...

Promo Image

Prevention of Mother-to-Child Transmission

There's nothing like hearing the results of studies directly from those who actually conducted the research. In this summary, you'll hear Louise Kuhn, Ph.D., Associate Professor of Epidemiology in the Gertrude H. Sergievsky Center, College of Physici...